touchMDT Precision targeting of MET in NSCLC: A multidisciplinary approach
A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.
Overview & Learning ObjectivesPatient with NSCLC with MET aberration
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
Get the Audio VersionWatch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of an 81-year-old patient with NSCLC, and highlight best practices for molecular biomarker testing to identify METex14 skipping mutations.
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
Get the Audio VersionWatch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss the case of an 81-year-old patient with NSCLC with METex14 skipping mutation, and provide practical insights on treatment selection and patient management.
Thoracic medical oncologist, interventional pulmonologist and molecular pathologist
Get the Audio VersionMetastatic challenges: Exploring MET amplification in refractory disease
COMING SOON: 14 NOV 24
Watch a thoracic medical oncologist, an interventional pulmonologist and a molecular pathologist discuss the case of a patient with EGFR-TKI refractory NSCLC, including how to monitor and test for resistance to EGFR-TKIs and how to interpret molecular data to inform treatment decisions.
Thoracic medical oncologist, clinical oncology pharmacist and oncology nurse practitioner
Get the Audio VersionNavigating resistance: MET-targeted treatment strategies for refractory NSCLC
COMING SOON: 14 NOV 24
Watch a thoracic medical oncologist, a clinical oncology pharmacist and an oncology nurse practitioner discuss treatment options and optimal management of a patient with EGFR-mutant NSCLC who develops resistance to EGFR-TKIs due to MET amplification.